omalizumab (Xolair®)

Policy # 00222
Original Effective Date: 09/19/2007
Current Effective Date: 05/08/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Asthma
Based on review of available data, the Company may consider omalizumab (Xolair®) for the management of moderate to severe persistent asthma to be eligible for coverage.**

Patient Selection Criteria
Coverage eligibility for the use of omalizumab (Xolair) will be considered for the treatment of moderate persistent or severe persistent asthma when all of the following criteria are met:

Initial Authorization:

I. Patient has a diagnosis of moderate persistent or severe persistent asthma; AND
II. Patient is 6 years of age or older; AND
III. Patient has a positive skin test or in vitro reactivity to a perennial aeroallergen; AND
IV. Xolair is NOT being used in combination with other monoclonal antibodies typically used to treat asthma (e.g., reslizumab (Cinqair®), mepolizumab (Nucala®), benralizumab (Fasenra®), dupilumab (Dupixent®)); AND
V. Patient has received at least 3 consecutive months of combination therapy with BOTH of the following (a and b):
   (Note that the 3 month timeframe is an additional Company requirement and will be denied as not medically necessary** if not met):
   a) An inhaled corticosteroid (ICS) (e.g. fluticasone products (Flovent® HFA, Flovent® Diskus®, Arnuity™ Ellipta®, Armonair™ Respliclick®), mometasone products (Asmanex® Twisthaler®, Asmanex® HFA), flunisolide products (Aerospan®),...
omalizumab (Xolair®)

Policy # 00222
Original Effective Date: 09/19/2007
Current Effective Date: 05/08/2023

ciclesonide products (Alvesco®), budesonide products (Pulmicort Flexhaler®), beclomethasone products (QVAR®); AND
b) At least ONE of the following (1, 2, 3, OR 4):
   1) Inhaled long-acting beta-agonist (LABA) [e.g., salmeterol products (Serevent® Diskus), olodaterol products (Striverdi® Respimat®), indacaterol products (Arcapta™ Neohaler™)]; OR
   NOTE: Use of a combination inhaler containing both an ICS and a LABA would fulfill the requirement for both criteria a.) and b.) [e.g. fluticasone propionate and salmeterol inhalation powder/aerosol (Advair® Diskus/HFA, fluticasone/salmeterol generics, Wixela™ Inhub, AirDuo™ Respliclick), budesonide and formoterol fumarate inhalation aerosol (Symbicort®), fluticasone furoate and vilanterol inhalation powder (Breo® Ellipta®), mometasone furoate and formoterol fumarate inhalation aerosol (Dulera®)].
   2) Inhaled long-acting muscarinic antagonist (LAMA) [e.g. tiotropium bromide inhalation spray (Spiriva® Respimat®, Stiolt® Respimat®), aclindinium products (Tudorza® Pressair®, generics), glycopyrrolate products (Seebri™ Neohaler, Bevespi™ Aerosphere, Utibron™ Neohaler), umeclidinium products (Incruse® Ellipta, Anoro® Ellipta)]; OR
   3) Leukotriene receptor antagonist (LTRA) [e.g. montelukast tablets/granules (Singulair®, generics), zafirlukast tablets (Accolate®)]; OR
   4) Theophylline (Theo-24, Uniphyll, TheoChron ER, generics); AND
   (Note that the combination of one of the items 1-4 above with an inhaled corticosteroid is an additional company requirement and will be denied as not medically necessary** if not met)

VI. Patient has the following serum IgE levels based on their age:
   a) Patients 12 years of age or older: ≥30 IU/mL to 700 IU/mL; OR
   b) Patients 6 to <12 years of age: ≥30 IU/mL to 1300 IU/mL; AND

VII. Xolair is ordered by a pulmonologist, allergist, or appropriate specialist; AND
   (Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

VIII. Patient’s asthma continues to be uncontrolled as defined by ONE of the following (a, b, c, d, or e):
   a) Patient experienced two or more asthma exacerbations requiring treatment with systemic corticosteroids in the previous year; OR

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
omalizumab (Xolair®)

Policy #  00222
Original Effective Date:  09/19/2007
Current Effective Date:  05/08/2023

b) Patient experienced one or more asthma exacerbation requiring hospitalization or an Emergency Department (ED) visit in the previous year; OR
c) Patient has a forced expiratory volume in 1 second (FEV₁) < 80% predicted; OR
d) Patient has an FEV₁/forced vital capacity (FVC) < 0.80; OR
e) Patient’s asthma worsens upon tapering of oral corticosteroid therapy; AND

Re-Authorization
Coverage continuation for omalizumab (Xolair) will be considered for the treatment of moderate persistent or severe persistent asthma when the following criteria are met:

I. Patient received an initial authorization for the requested drug; AND

II. Xolair is NOT being used in combination with other monoclonal antibodies typically used to treat asthma [e.g., reslizumab (Cinqair), mepolizumab (Nucala), benralizumab (Fasenra), dupilumab (Dupixent)]; AND

III. Patient continues to receive the medications required in criterion V. in the “Initial Criteria”; AND

(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

IV. Patient has responded to Xolair therapy as determined by the prescribing physician [e.g., decreased asthma exacerbations; decreased asthma symptoms; decreased hospitalizations, emergency department (ED)/urgent care, or physician visits due to asthma; decreased requirement for oral corticosteroid therapy.]

(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

Chronic Spontaneous Urticaria
Based on review of available data, the Company may consider omalizumab (Xolair) for the treatment of chronic spontaneous urticaria to be eligible for coverage.**

Patient Selection Criteria
Coverage eligibility for the use of omalizumab (Xolair) for the treatment of chronic spontaneous urticaria will be considered when all of the following criteria are met:
omalizumab (Xolair®)

Policy #  00222
Original Effective Date:  09/19/2007
Current Effective Date:  05/08/2023

Initial Authorization:
I.  Patient has a diagnosis of Chronic Spontaneous Urticaria (defined by the presence of itchy hives that last for at least 6 weeks, with or without angioedema, and have no apparent external trigger); AND
II.  Patient is 12 years of age or older; AND
III.  Xolair is dosed 150 mg or 300 mg every 4 weeks; AND
IV.  Patient remains symptomatic despite at least 6 weeks of treatment with standard therapeutic doses of H1 antihistamine (e.g., cetirizine 10 mg, levocetirizine 5 mg, fexofenadine 180 mg) AND leukotriene modifier combination therapy (e.g., montelukast 10 mg).
(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)

Re-Authorization
Coverage continuation for omalizumab (Xolair) will be considered for the treatment of chronic spontaneous urticaria when the following criteria are met:
I.  Patient received an initial authorization for the requested drug; AND
II.  Xolair is dosed 150 mg or 300 mg every 4 weeks; AND
III.  Patient has responded to Xolair therapy as determined by the prescribing physician (e.g., reduction in exacerbations, itch severity, hives).
(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

Nasal Polyps
Based on review of available data, the Company may consider omalizumab (Xolair) for the treatment of nasal polyps to be eligible for coverage.**

Patient Selection Criteria
Coverage eligibility for the use of omalizumab (Xolair) will be considered for the treatment of nasal polyps when all of the following criteria are met:
Initial Authorization:
I.  Patient has a diagnosis of inadequately controlled nasal polyps; AND
II.  Patient is 18 years of age or older; AND
III.  Patient has recurrent polyposis after at least ONE surgical resection (unless resection is contraindicated); AND

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
omalizumab (Xolair®)

Policy # 00222
Original Effective Date: 09/19/2007
Current Effective Date: 05/08/2023

(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

IV. Patient’s nasal polyposis has been confirmed as grade 3 or higher with nasal endoscopy; AND
(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

V. Patient’s polyposis recurrence occurred within 6 months of at least one high dose oral steroid taper after the most recent resection unless there is clinical evidence or patient history that suggests the use of a high dose oral steroid taper will be ineffective or cause an adverse effect to the patient; AND
(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

VI. Patient has tried and failed (e.g., intolerance or inadequate response) BOTH fluticasone 50 mcg (generic OR over the counter) AND GENERIC mometasone after least 30 days with EACH product unless there is clinical evidence or patient history that suggests the use of these nasal sprays will be ineffective or cause an adverse effect to the patient; AND
(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

VII. Patient has tried and failed (e.g., intolerance or inadequate response) Xhance®‡ (fluticasone 93 mcg) after at least 30 days of therapy unless there is clinical evidence or patient history that suggests the use of Xhance (fluticasone 93 mcg) will be ineffective or cause an adverse effect to the patient; AND
(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

VIII. Patient has tried and failed (e.g., intolerance or inadequate response) GENERIC montelukast after at least 30 days of therapy unless there is clinical evidence or patient history that suggests the use of GENERIC montelukast will be ineffective or cause an adverse effect to the patient; AND
(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

IX. Patient will continue to use an intra-nasal corticosteroid (e.g., fluticasone, mometasone, Xhance) in combination with Xolair (if the intra-nasal corticosteroid was tolerated); AND

X. Patient will NOT use Xolair in combination with other biologics used to treat nasal polyps (e.g., Dupixent); AND
omalizumab (Xolair®)

Policy # 00222
Original Effective Date: 09/19/2007
Current Effective Date: 05/08/2023

XI. Patient has an IgE level of ≥30 IU/mL to 1500 IU/mL.

Re-Authorization
Coverage continuation for omalizumab (Xolair) will be considered for the treatment of inadequately controlled nasal polyps when the following criteria are met:

I. Patient has received an initial authorization; AND
II. Patient will continue to use an intra-nasal corticosteroid (e.g., fluticasone, mometasone, Xhance) in combination with Xolair (if the intra-nasal corticosteroid was tolerated); AND
III. Patient will NOT use Xolair in combination with other biologics used to treat nasal polyps (e.g., Dupixent); AND
IV. Patient has responded to requested therapy as determined by the prescribing physician (e.g., decrease in nasal polyps, decreased congestion/obstruction, etc.).
(Note: This specific patient criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met).

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers the use of omalizumab (Xolair) when any of the following patient selection criteria for the requested diagnosis are NOT met to be not medically necessary:**

- Asthma
  - Patient has used one of the following in combination with an inhaled corticosteroid prior to requesting Xolair: 1) inhaled long acting beta agonist; 2) inhaled long acting muscarinic antagonist; 3) leukotriene receptor antagonist; 4) theophylline
  - Patient has been on the listed pre-requisite asthma medications (criteria V.) for at least 3 months
  - Xolair is ordered by a pulmonologist, allergist, or appropriate specialist
  - For re-authorization requests: Patient has responded to requested therapy as determined by the prescribing physician (e.g., decreased asthma exacerbations; decreased asthma symptoms; decreased hospitalizations, ED/urgent care, or physician visits due to asthma; decreased requirement for oral corticosteroid therapy).

- Chronic Spontaneous Urticaria
  - Patient remains symptomatic despite at least 6 weeks of treatment with standard therapeutic doses of H1 antihistamine (e.g., cetirizine 10 mg, levocetirizine 5 mg,
omalizumab (Xolair®)

Policy # 00222
Original Effective Date: 09/19/2007
Current Effective Date: 05/08/2023

- fexofenadine 180 mg) AND leukotriene modifier combination therapy (e.g., montelukast 10 mg)
  - For re-authorization requests: Patient has responded to Xolair therapy as determined by the prescribing physician (e.g., reduction in exacerbations, itch severity, hives).

- Nasal Polyps
  - Patient has recurrent polyposis after at least ONE surgical resection (unless resection is contraindicated)
  - Patient’s nasal polyposis has been confirmed as grade 3 or higher with nasal endoscopy
  - Patient’s polyposis recurrence occurred within 6 months of at least one high dose oral steroid taper after the most recent resection
  - Patient has tried and failed (e.g., intolerance or inadequate response) BOTH fluticasone 50 mcg (generic OR over the counter) AND GENERIC mometasone after least 30 days with EACH product
  - Patient has tried and failed (e.g., intolerance or inadequate response) Xhance (fluticasone 93 mcg) after at least 30 days of therapy
  - Patient has tried and failed (e.g., intolerance or inadequate response) GENERIC montelukast after at least 30 days of therapy
  - For re-authorization requests: Patient has responded to requested therapy as determined by the prescribing physician (e.g., decrease in nasal polyps, decreased congestion/obstruction, etc.).

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of omalizumab (Xolair) when the patient selection criteria are not met (EXCEPT those denoted as not medically necessary**) to be investigational.*

Based on review of available data, the Company considers the use of omalizumab (Xolair) for any non-FDA approved indication to be investigational.*
omalizumab (Xolair®)

Policy # 00222
Original Effective Date: 09/19/2007
Current Effective Date: 05/08/2023

**Background/Overview**

Xolair is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is approved for the treatment of: 1) moderate to severe persistent asthma in patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids; 2) chronic spontaneous urticaria in adults and adolescents 12 years of age and older who remain symptomatic despite H₁ antihistamine treatment; and 3) nasal polyps in adult patients with an inadequate response to nasal corticosteroids, as an add on maintenance treatment. Xolair is administered subcutaneously once or twice a month for the asthma and nasal polyps indications and the dose is based on total serum IgE concentrations and body weight prior to therapy. Chronic spontaneous urticaria dosing is once monthly and is not weight or serum IgE level dependent.

**Asthma**

Asthma is a respiratory disorder characterized by increased responsiveness of the trachea and bronchi to various stimuli resulting in the narrowing of the airways, along with mucous secretion. Symptoms vary in severity and intensity and include wheezing, cough and dyspnea. Attacks can be triggered by exercise, allergens, irritants and viral infections. Based on symptoms, the four levels of asthma severity are:

- **Mild intermittent (comes and goes)**—you have episodes of asthma symptoms twice a week or less, and you are bothered by symptoms at night twice a month or less; between episodes, however, you have no symptoms and your lung function is normal.
- **Mild persistent asthma**—you have asthma symptoms more than twice a week, but no more than once in a single day. You are bothered by symptoms at night more than twice a month. You may have asthma attacks that affect your activity.
- **Moderate persistent asthma**—you have asthma symptoms every day, and you are bothered by nighttime symptoms more than once a week. Asthma attacks may affect your activity.
- **Severe persistent asthma**—you have symptoms throughout the day on most days, and you are bothered by nighttime symptoms often. In severe asthma, your physical activity is likely to be limited.
Chronic Spontaneous Urticaria
Chronic spontaneous urticaria (CSU) is defined by the presence of itchy hives that last for at least 6 weeks, with or without angioedema, and have no apparent external trigger. Typical treatments for CSU include antihistamines, leukotriene modifiers, and immunomodulatory agents.

Nasal Polyps
Chronic rhinosinusitis is an inflammatory condition involving the nasal sinuses and the lining of the nasal passages. Chronic rhinosinusitis often involves nasal drainage, nasal obstruction, facial pain and/or pressure and decreased sense of smell. Chronic rhinosinusitis with nasal polyposis is characterized by the presence of bilateral nasal polyps in the middle meatus. As imagined, these polyps lead to worsening nasal congestion, pressure, drainage, etc. Treatments for chronic rhinosinusitis with nasal polyposis includes various treatment modalities including, but not limited to, intranasal saline, intranasal steroids, oral steroids, surgery, non-sedating antihistamines, anti-leukotriene agents, and for those who have failed these more traditional therapies, biologics such as Xolair or Dupixent.

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
Xolair is approved to treat patients 6 years of age and above with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. In 2014, Xolair gained an indication for the treatment of chronic idiopathic urticaria in patients 12 years of age or older who remain symptomatic despite H1 antihistamine treatment. In mid-2016, the indication for asthma was expanded to those 6 years of age and older. In late 2020, Xolair gained an additional indication for the treatment of nasal polyps in adult patients with an inadequate response to nasal corticosteroids, as an add on maintenance treatment. It should be noted that in July 2021, the package insert was updated to reflect a change in indication from “chronic idiopathic urticaria” to “chronic spontaneous urticaria.”

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical
omalizumab (Xolair®)

Policy #  00222
Original Effective Date: 09/19/2007
Current Effective Date: 05/08/2023

practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Asthma
The initial asthma indication was based on data from three multicenter, randomized, double blind, placebo-controlled studies in over 1,400 patients 12 years of age or older with symptomatic moderate to severe persistent asthma for at least 1 year and a positive skin test reaction to a perennial aeroallergen. In 2 of the 3 studies, treatment with Xolair was associated with lower incidence of asthma exacerbations compared with placebo; the incidence of asthma exacerbations was similar between Xolair and placebo in study 3. No reduction in the incidence of asthma exacerbations was observed in patients with a baseline forced expiratory volume in 1 second exceeding 80% or in patients who required oral corticosteroids as maintenance therapy in any of the studies.

The expansion of age for those 6 years to less than 12 years for the asthma indication was based on a randomized, double-blind, placebo controlled, multi-center trial studying pediatric patients aged 6 to less than 12 years of age with moderate to severe asthma. This study was conducted over 52 weeks and was conducted on children who were inadequately controlled despite the use of inhaled corticosteroids with or without controller asthma medications. During the first 24 weeks, the steroid doses remained constant from baseline. The initial 24 week period was then followed with a 28 week period in which the inhaled corticosteroid adjustment was allowed. The primary endpoint was the rate of asthma exacerbations during the 24 week steroid treatment phase. At 24 weeks, the Xolair group had a statistically significantly lower rate of asthma exacerbations (0.45 vs. 0.64) with an estimated rate ratio of 0.69 (95% CI: 0.53, 0.90). The Xolair group also had a lower rate of asthma exacerbations compared to placebo over the full 52 week double blind treatment period (0.78 vs. 1.36; rate ratio 0.57; 95% CI: 0.45, 0.72). Other efficacy variables such as nocturnal symptom scores, beta agonist use, and measures of airflow (FEV₁) were not statistically significantly different in Xolair treated patients compared to placebo. Another trial lasting 28 weeks demonstrated similar results.

Chronic Spontaneous Urticaria
The safety and efficacy of Xolair for the treatment of CSU was assessed in two placebo-controlled, multiple-dose clinical studies of 24 weeks’ duration and 12 weeks’ duration. Patients received Xolair 75, 150, or 300 mg or placebo by subcutaneous injection every 4 weeks in addition to their baseline level of H₁ antihistamine therapy for 24 or 12 weeks, followed by a 16-week washout observation
omalizumab (Xolair®)

Policy # 00222
Original Effective Date: 09/19/2007
Current Effective Date: 05/08/2023

period. In both CSU Studies 1 and 2, patients who received Xolair 150 mg or 300 mg had greater decreases from baseline in weekly itch severity scores and weekly hive count scores than placebo at week 12. The 75 mg dose did not demonstrate consistent evidence of efficacy and is not approved for use.

Nasal Polyps
The safety and efficacy of Xolair was evaluated in two multicenter, double blind, placebo-controlled clinical trials that enrolled patients with nasal polyps with inadequate response to nasal corticosteroids (Nasal Polyps Trial 1, n=138; Nasal Polyps Trial 2, n=127). Patients received Xolair or placebo by subcutaneous injection every 2 or 4 weeks for 24 weeks followed by a 4-week follow-up period. All patients received background nasal mometasone therapy during both the treatment period and during a 5-week run-in period. Prior to randomization, patients were required to have evidence of bilateral polyps as determined by a nasal polyp score (NPS) ≥ 5 with NPS ≥ 2 in each nostril, despite use of nasal mometasone during the run-in period. NPS was measured via endoscopy and scored (range 0-4 per nostril: 0 = no polyps; 1 = small polyps in the middle meatus not reaching below the inferior border of the middle turbinate; 2 = polyps reaching below the lower border of the middle turbinate; 3 = large polyps reaching the lower border of the inferior turbinate or polyps medial to the middle turbinate; 4 = large polyps causing complete obstruction of the inferior nasal cavity) for a total NPS (range 0-8). Patients were furthermore required to have a weekly average of nasal congestion score (NCS) > 1 prior to randomization, despite use of nasal mometasone. Nasal congestion was measured by a daily assessment on a 0 to 3 point severity scale (0 = none, 1 = mild, 2 = moderate, 3 = severe). The co-primary endpoints in Trials 1 and 2 were NPS and average daily NCS at week 24. The difference in least square means in placebo as compared to Xolair for the NPS was -1.1 and -0.6 in Trials 1 and 2, respectively. The difference in least square means in placebo as compared to Xolair for the NCS was -0.6 and -0.5 in Trials 1 and 2, respectively. In both trials, patients who received Xolair had a statistically significant greater improvement from baseline at week 24 in NPS and weekly average NCS, than patients who received placebo.

References
omalizumab (Xolair®)

Policy # 00222
Original Effective Date: 09/19/2007
Current Effective Date: 05/08/2023


Policy History
Original Effective Date: 09/19/2007
Current Effective Date: 05/08/2023

09/05/2007 Medical Director review
09/19/2007 Medical Policy Committee approval.
09/09/2008 Medical Director review
09/17/2008 Medical Policy Committee approval. No change to coverage eligibility. Added FDA black box warning to FDA section.
09/03/2009 Medical Policy Committee approval
09/16/2009 Medical Policy Implementation Committee approval. No change to coverage eligibility.
09/09/2010 Medical Policy Committee review
09/01/2011 Medical Policy Committee review
09/14/2011 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
11/01/2012 Medical Policy Committee review
02/07/2013 Medical Policy Committee review
omalizumab (Xolair®)

Policy #  00222
Original Effective Date:  09/19/2007
Current Effective Date:  05/08/2023

02/20/2013  Medical Policy Implementation Committee approval. “When services are not covered” section was deleted from policy. Patient selection criteria revised.
05/01/2014  Medical Policy Committee review
05/21/2014  Medical Policy Implementation Committee approval. Added indication for CIU and updated FDA, background, and rationale sections to reflect change.
05/07/2015  Medical Policy Committee review
05/20/2015  Medical Policy Implementation Committee approval. No change to coverage.
05/05/2016  Medical Policy Committee review
05/18/2016  Medical Policy Implementation Committee approval. No change to coverage.
09/08/2016  Medical Policy Committee review
09/21/2016  Medical Policy Implementation Committee approval. Changed the age for the asthma indication to 6 years or older based on updated package insert indication.
01/01/2017  Coding update: Removing ICD-9 Diagnosis Codes
09/07/2017  Medical Policy Committee review
09/20/2017  Medical Policy Implementation Committee approval. Clarified that this drug can’t be combined with other monoclonal antibodies that typically treat asthma.
09/06/2018  Medical Policy Committee review
09/19/2018  Medical Policy Implementation Committee approval. No change to coverage.
09/05/2019  Medical Policy Committee review
09/11/2019  Medical Policy Implementation Committee approval. Added newer products to list of products that aren’t to be used in combination with Xolair.
09/03/2020  Medical Policy Committee review
09/09/2020  Medical Policy Implementation Committee approval. No change to coverage.
04/01/2021  Medical Policy Committee review
04/14/2021  Medical Policy Implementation Committee approval. Updated the asthma section of the criteria to be more consistent with latest guidance on asthma and more consistent with other biologics approved for the treatment of asthma. Added a new FDA approved indication for nasal polyps. Updated relevant background information.
04/07/2022  Medical Policy Committee review
04/13/2022  Medical Policy Implementation Committee approval. For nasal polyps, changed the surgical resection requirement from two to one. Changed “chronic idiopathic urticaria” to “chronic spontaneous urticaria” to match the updated package insert.
04/06/2023  Medical Policy Committee review

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
omalizumab (Xolair®)

Policy #  00222
Original Effective Date:  09/19/2007
Current Effective Date:  05/08/2023

04/12/2023   Medical Policy Implementation Committee approval. No change to coverage.
Next Scheduled Review Date:  04/2024

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, misuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>No codes</td>
</tr>
<tr>
<td>HCPCS</td>
<td>J2357</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
omalizumab (Xolair®)

Policy #  00222
Original Effective Date:  09/19/2007
Current Effective Date:  05/08/2023

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:
  A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
  B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
     1. Consultation with technology evaluation center(s);
     2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
     3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:
  A. In accordance with nationally accepted standards of medical practice;
  B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
  C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
omalizumab (Xolair®)

Policy #  00222  
Original Effective Date:  09/19/2007  
Current Effective Date:  05/08/2023

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE:  If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE:  Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.